Apatinib as Salvage Therapy for Heavily Pretreated SCLC / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 565-570, 2018.
Article
in Zh
| WPRIM
| ID: wpr-772400
Responsible library:
WPRO
ABSTRACT
Small cell lung cancer (SCLC) was highly malignant and lack effective treatment after the failure of radiotherapy and chemotherapy. Antiangiogenic therapy had shown a certain effect in advanced SCLC. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), showed the effect of anti-angiogenesis. However, the efficacy in SCLC was rarely reported. We reported 1 case of advanced SCLC with Gilbert syndrome, the patient received Apatinib after the failure of 4 lines of chemotherapy, and achieved a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard after one month. The progression-free survival (PFS) was 5 months. Apatinib was well tolerated except recurrent grade 3 hyperbilirubinemia because of the metabolic disorder of Bilirubin. Salvage treatment with Apatinib for advanced SCLC deserved further exploration.
.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Pyridines
/
Diagnostic Imaging
/
Tomography, X-Ray Computed
/
Treatment Outcome
/
Salvage Therapy
/
Disease-Free Survival
/
Therapeutic Uses
/
Diagnosis
/
Drug Therapy
/
Small Cell Lung Carcinoma
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2018
Type:
Article